# sacituzumab tirumotecan, or sac-TMT, showed a statistically significant and clinically meaningful improvement in both overall survival and how long patients lived before their disease worsened.

*biotech · news · 2026-05-18 · Reuters*

## Key points

- sac-TMT achieved statistically significant improvement in survival versus chemotherapy in endometrial cancer trial.
- The trial included 776 patients with advanced or recurrent endometrial cancer pretreated with platinum and immunotherapy.
- sac-TMT targets tumor cells by binding to the TROP2 protein, delivering chemotherapy directly.
- FDA has selected sac-TMT for its National Priority Voucher program, potentially expediting review to as little as one month.

**Countries:** United States, India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-endometrial-cancer-drug-meets-late-stage-trial-goals-2026-05-18/)

---

Canonical: https://newsio.io/n/d494f778-da0f-4ff9-9348-0aa6f30d2505/sacituzumab-tirumotecan-or-sac-tmt-showed-a-statistically-significant-and-clinic
Summarized by Newsio from Reuters. https://newsio.io/how-it-works